Kailera Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2024, focused on developing next-generation injectable and oral GLP-1 therapies for obesity treatment. The company operates from locations in Waltham, Massachusetts, and San Diego, California. It launched with substantial funding to support its research and development activities.
The company's lead product candidate is KAI-9531 (ribupatide), a once-weekly injectable GLP-1/GIP receptor dual agonist currently in Phase 3 development. This places the therapy in advanced clinical trials for potential obesity treatment. The company's work spans the biotechnology, pharmaceuticals, and metabolic health research domains.
Kailera Therapeutics describes its internal culture as emphasizing collaboration, integrity, and scientific excellence. It seeks to foster innovation through curious and passionate professionals within an inclusive, team-oriented environment that values diverse perspectives and entrepreneurial thinking.
